Target Name: LMNA
NCBI ID: G4000
Other Name(s): EMD2 | LMNA variant 3 | Lamin A/C-like 1 | lamin | LMNA variant 1 | CMT2B1 | CDDC | HGPS | LMNC | Progeria 1 (Hutchinson-Gilford type) | prelamin-A/C | OTTHUMP00000015845 | epididymis secretory sperm binding protein | Lamin A/C, transcript variant 6 | FPL | CDCD1 | LMN1 | IDC | OTTHUMP00000015843 | Lamin A/C, transcript variant 1 | LDP1 | Prelamin-A/C (isoform C) | LMNA variant 2 | Lamin A/C, transcript variant 2 | 70 kDa Lamin | Lamin A/C (isoform 1) | Lamin A/C, transcript variant 4 | LMNA_HUMAN | MADA | Prelamin-A/C (isoform A-delta10) | LMNA variant 4 | LMNA variant 7 | OTTHUMP00000015848 | OTTHUMP00000015846 | Prelamin-A/C | Lamin A/C, transcript variant 3 | mandibuloacral dysplasia type A | Prelamin-A/C (isoform A-delta50) | Prelamin-A/C (isoform D) | PRO1 | Lamin C | FPLD2 | lamin A/C-like 1 | renal carcinoma antigen NY-REN-32 | Charcot-Marie-Tooth disease, axonal, type 2B1 | CMD1A | LFP | Prelamin-A/C (isoform A) | FPLD | LGMD1B | lamin A/C | OTTHUMP00000217835 | C | Renal carcinoma antigen NY-REN-32 | Lamin-A/C | OTTHUMP00000015847 | Lamin A/C, transcript variant 7 | 70 kDa lamin | LMNL1 | Lamin A

LMNA: A Potential Drug Target for Various Diseases

LMNA (LMN-associated protein 1) is a protein that is expressed in various tissues and organs, including the brain, heart, and kidneys. It is a member of the LMN (long non-coding RNA) family, which has been identified as a potential drug target in various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases.

LMNA is known for its role in the regulation of gene expression and has been shown to play a role in a variety of physiological processes, including cell growth, apoptosis, and inflammation. It is also involved in the development and progression of certain diseases, including neurofibrillary tangles and neurodegenerative diseases.

Recent studies have suggested that LMNA may be a potential drug target for a variety of conditions, including Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders. These studies have identified potential LMNA-targeted compounds that have been shown to interact with LMNA and enhance its activity, leading to the possibility that these compounds may be effective in treating these diseases.

Additionally, LMNA has also been shown to be involved in the regulation of pain perception and neuroinflammation. Therefore, it is also a potential drug target for pain management and neuroinflammation treatments.

LMNA is also known to play a role in the development and progression of certain cardiovascular diseases, including heart failure, hypertension, and stroke. It is suggested that by targeting LMNA, researchers may be able to develop new treatments for these conditions.

Overall, LMNA is a protein that has the potential to be a drug target for a variety of diseases. Further research is needed to fully understand its role in these diseases and to develop effective treatments.

Protein Name: Lamin A/C

Functions: Lamins are components of the nuclear lamina, a fibrous layer on the nucleoplasmic side of the inner nuclear membrane, which is thought to provide a framework for the nuclear envelope and may also interact with chromatin (PubMed:10080180, PubMed:10580070, PubMed:10587585, PubMed:10814726, PubMed:11799477, PubMed:12075506, PubMed:12927431, PubMed:15317753, PubMed:18551513, PubMed:18611980, PubMed:22431096, PubMed:23666920, PubMed:31548606). Lamin A and C are present in equal amounts in the lamina of mammals (PubMed:10080180, PubMed:10580070, PubMed:10587585, PubMed:10814726, PubMed:11799477, PubMed:12075506, PubMed:12927431, PubMed:15317753, PubMed:18551513, PubMed:18611980, PubMed:22431096, PubMed:23666920, PubMed:31548606). Recruited by DNA repair proteins XRCC4 and IFFO1 to the DNA double-strand breaks (DSBs) to prevent chromosome translocation by immobilizing broken DNA ends (PubMed:31548606). Plays an important role in nuclear assembly, chromatin organization, nuclear membrane and telomere dynamics. Required for normal development of peripheral nervous system and skeletal muscle and for muscle satellite cell proliferation (PubMed:10080180, PubMed:10814726, PubMed:11799477, PubMed:18551513, PubMed:22431096). Required for osteoblastogenesis and bone formation (PubMed:12075506, PubMed:15317753, PubMed:18611980). Also prevents fat infiltration of muscle and bone marrow, helping to maintain the volume and strength of skeletal muscle and bone (PubMed:10587585). Required for cardiac homeostasis (PubMed:10580070, PubMed:12927431, PubMed:23666920, PubMed:18611980)

More Common Targets

LMNB1 | LMNB2 | LMNTD1 | LMNTD2 | LMNTD2-AS1 | LMO1 | LMO2 | LMO3 | LMO4 | LMO7 | LMO7-AS1 | LMO7DN | LMOD1 | LMOD2 | LMOD3 | LMTK2 | LMTK3 | LMX1A | LMX1B | LMX1B-DT | LNC-LBCS | LNCAROD | LNCARSR | LNCATV | LNCNEF | LNCOC1 | LNCOG | LNCPRESS1 | LNCRI | LNCRNA-ATB | LNCRNA-IUR | LNCTAM34A | LNP1 | LNPEP | LNPK | LNX1 | LNX1-AS1 | LNX2 | LOC100127946 | LOC100127955 | LOC100128002 | LOC100128028 | LOC100128050 | LOC100128059 | LOC100128079 | LOC100128093 | LOC100128164 | LOC100128242 | LOC100128288 | LOC100128317 | LOC100128361 | LOC100128398 | LOC100128494 | LOC100128593 | LOC100128770 | LOC100128966 | LOC100128988 | LOC100129034 | LOC100129098 | LOC100129148 | LOC100129175 | LOC100129203 | LOC100129215 | LOC100129316 | LOC100129381 | LOC100129434 | LOC100129455 | LOC100129534 | LOC100129603 | LOC100129697 | LOC100130000 | LOC100130207 | LOC100130285 | LOC100130298 | LOC100130331 | LOC100130452 | LOC100130463 | LOC100130548 | LOC100130587 | LOC100130691 | LOC100130698 | LOC100130744 | LOC100130748 | LOC100130872 | LOC100130899 | LOC100130938 | LOC100130987 | LOC100130992 | LOC100131096 | LOC100131107 | LOC100131257 | LOC100131289 | LOC100131372 | LOC100131496 | LOC100131532 | LOC100131626 | LOC100131635 | LOC100131859 | LOC100131877 | LOC100131943